Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over
Conclusion The results of this study support the preferential prescription of moderate-intensity rosuvastatin over moderate-intensity atorvastatin for the secondary prevention of ischemic cardiovascular and cerebrovascular events in older patients aged ≥ 75 years.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
More News: Aspirin | Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Crestor | Databases & Libraries | Diabetes | Diabetes Mellitus | Drugs & Pharmacology | Endocrinology | Health Insurance | Heart | Insurance | Lipitor | Rosuvastatin | South Korea Health | Statin Therapy | Study | Zivast